Skip to main content

Press releases | November 14, 2022

Fried Frank acted as counsel to Lazard as financial advisor to Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) in its approximately $145 million sale to Indivior PLC (LON: INDV). Opiant Pharmaceuticals is a biopharmaceutical company developing treatments for addiction and drug overdose leveraging intranasal and injectable delivery technologies. Indivior is a specialty pharmaceuticals business.

The Fried Frank team was led by partner Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.